JOHANNESBURG, June 18 (Reuters) - Aspen Pharmacare said on Tuesday it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drug from GlaxoSmithKline, except in China, Pakistan and India.

LONDON, June 18 (Reuters) - GlaxoSmithKline said on Tuesday that South Africa's Aspen Pharmacare had offered to acquire its thrombosis drug brands Arixtra and Fraxiparine, along with the related manufacturing site.

LONDON, June 18 (Reuters) - GlaxoSmithKline said on Tuesday that South Africa's Aspen Pharmacare had offered to acquire its thrombosis drug brands Arixtra and Fraxiparine, along with the related manufacturing site.

LONDON, June 18 (Reuters) - GlaxoSmithKline said on Tuesday that South Africa's Aspen Pharmacare had offered to acquire its thrombosis drug brands Arixtra and Fraxiparine, along with the related...

Oil firms lead U.K. stocks higher after a broker upgrade on Monday, while shares of GlaxoSmithKline PLC also show upbeat moves after a target price lift.

GlaxoSmithKline is investigating allegations from an anonymous tipster that its sales staff in China was involved in widespread bribery of doctors to prescribe drugs, in some cases for unauthorized uses.

Before you invest another penny in GlaxoSmithKline, let's look at cash flow, debt and dividends.

LONDON, June 12 (Reuters) - GlaxoSmithKline has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade, after offering a price discount to the country's state-run healthcare service.

GlaxoSmithKline said it fired its head of R&D in China after discovering a paper he helped write for Nature Medicine had "misrepresented" data.

LONDON (Reuters) - British drugmaker GlaxoSmithKline has fired its head of research and development in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data.

LONDON, June 11 (Reuters) - British drugmaker GlaxoSmithKline has fired its head of research and development in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data.

LONDON, June 11 (Reuters) - British drugmaker GlaxoSmithKline has fired its head of research and development in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data.

ByRenee Butler:Opportunities for investors in the pharmaceutical industry are not limited to new companies with breakthrough products -- or breakthrough products at all for that reason. In fact, sometimes a good product gets a bad wrap and comes back

By Derek Lowe: The accusations of data fabrication at GlaxoSmithKline's (GSK) China research site are quite real. That's what we get from the latest developments in the case, as reported by BioCentury, Pharmalot, and the news section at Nature Medici

WASHINGTON, June 6 (Reuters) - U.S. health advisers voted on Thursday to recommend relaxing market restrictions on GlaxoSmithKline's diabetes drug Avandia, the former blockbuster at the center of one of the biggest drug controversies in recent years.

WASHINGTON, June 6 (Reuters) - U.S. health advisers voted on Thursday to recommend modifying market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent yea

WASHINGTON, June 6 (Reuters) - A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of

WASHINGTON, June 6 (Reuters) - A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of

WASHINGTON, June 6 (Reuters) - A narrowly divided U.S. Foodand Drug Administration panel of outside experts on Thursdayvoted to modify market restrictions on GlaxoSmithKline's diabetes drug...

June 5 (Reuters) - A panel of medical advisers to the U.S.Food and Drug Administration will revive a six-year-old debateover the safety of GlaxoSmithKline Plc's Avandiadiabetes drug, but the...

June 5 (Reuters) - A panel of medical advisers to the U.S. Food and Drug Administration will revive a six-year-old debate over the safety of GlaxoSmithKline Plc's Avandia diabetes drug, but the two-day meeting that starts on Wednesday is not expected

June 3 (Reuters) - An independent analysis of a controversial clinical trial appears to back the safety of GlaxoSmithKline Plc's diabetes drug Avandia, U.S. regulators said on Monday, although scores of smaller trials still raise questions over wheth

June 3 (Reuters) - An independent analysis of a controversial clinical trial appears to back the safety of GlaxoSmithKline Plc's diabetes drug Avandia, U.S. regulators said on Monday, although scores of smaller trials still raise questions over wheth

LONDON, June 3 (Reuters) - GlaxoSmithKline said on Monday that its breast cancer drug lapatinib in combination with chemotherapy did not improve survival rates for patients with gastric cancer compared to the use of chemotherapy alone.

CHICAGO, June 1 (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening.

CHICAGO, June 1 (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening.

CHICAGO, June 1 (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend survival by several months for ovarian cancer patents whose disease had returned after initial surgery and chemotherapy.

CHICAGO, June 1 (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend survival by several months for ovarian cancer patents whose disease had returned after initial surgery and chemotherapy.

LONDON, May 31 (Reuters) - Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday

LONDON, May 31 (Reuters) - Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday

LONDON, May 31 (Reuters) - Use of an epilepsy drug developedby GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epilepticmedicines have proved...

ByFund Gurus:Many large cap pharmaceuticals have been taking hits to their revenue as patents for a number of key drugs run out. With future revenue under threat, pipeline drug production and streamlining business is now becoming more fundamental. Ha

ByFund Gurus:Many large cap pharmaceuticals have been taking hits to their revenue as patents for a number of key drugs run out. With future revenue under threat, pipeline drug production and streamlining business is now becoming more fundamental. Ha

May 29 (Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations. It also approved a diagnostic test to de

May 29 (Reuters) - U.S. health regulators on Wednesdayapproved a pair of GlaxoSmithKline Plc drugs to treatadvanced melanoma - the deadliest form of skin cancer - inpatients with specific genetic...

The transaction will expand the global pharma leader's vaccine platform technology.

May 29 (Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations, along with a diagnostic test to detect t

May 29 (Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations, along with a diagnostic test to detect t

May 29 (Reuters) - U.S. health regulators on Wednesdayapproved a pair of GlaxoSmithKline Plc drugs to treatadvanced melanoma - the deadliest form of skin cancer - inpatients with specific genetic...

GlaxoSmithKline (NYSE: GSK) won approval for two drugs to treat advanced skin cancer that are accompanied by diagnostic tests to help target the treatments.The Food and Drug Administration approved Tafinlar and Mekinist for patients with melanoma, th

LONDON, May 29 (Reuters) - GlaxoSmithKline Plc : * Positive top-line phase 3 results from trial of Arzerra (ofatumumab) combined

Genmab A/S and GlaxoSmithKline plc (NYSE: GSK) announced today that theirPhase III study of ARZERRA^(R) (ofatumumab) in combination with chlorambucilversus chlorambucil alone in patients with previously untreated chroniclymphocytic leukemia (CLL) me

GlaxoSmithKline is paying $321.4 million to buy a closely held Swiss company whose technology it hopes will speed up the development of vaccines in hotly pursued areas including hepatitis C, HIV and malaria.

LONDON, May 29 (Reuters) - GlaxoSmithKline boosted its vaccine business on Wednesday by agreeing to acquire Swiss-based vaccine technology company Okairos for 250 million euros ($321 million).

LONDON, May 29 (Reuters) - GlaxoSmithKline boosted its vaccine business on Wednesday by agreeing to acquire Swiss-based vaccine technology company Okairos for 250 million euros ($321 million).

LONDON, May 29 (Reuters) - GlaxoSmithKline boosted its vaccine business on Wednesday by agreeing to acquire Swiss-based vaccine technology company Okairos for 250 million euros ($321 million).

Analysts shift stance on GlaxoSmithKline, St. Jude Medical, and Abbott Labs.

GlaxoSmithKline may be losing confidence in Prosensa, which helps Sarepta. Click to view a price quote on SRPT. Click to research the Drugs industry.